CN115636833B - 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途 - Google Patents

作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途 Download PDF

Info

Publication number
CN115636833B
CN115636833B CN202211142049.1A CN202211142049A CN115636833B CN 115636833 B CN115636833 B CN 115636833B CN 202211142049 A CN202211142049 A CN 202211142049A CN 115636833 B CN115636833 B CN 115636833B
Authority
CN
China
Prior art keywords
methyl
cinnolin
fluoro
imidazo
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211142049.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN115636833A (zh
Inventor
周鼎
程子强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Zanrong Medical Technology Co ltd
Original Assignee
Suzhou Zanrong Medical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Zanrong Medical Technology Co ltd filed Critical Suzhou Zanrong Medical Technology Co ltd
Priority to CN202211142049.1A priority Critical patent/CN115636833B/zh
Publication of CN115636833A publication Critical patent/CN115636833A/zh
Application granted granted Critical
Publication of CN115636833B publication Critical patent/CN115636833B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202211142049.1A 2018-09-14 2019-09-16 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途 Active CN115636833B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211142049.1A CN115636833B (zh) 2018-09-14 2019-09-16 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018105675 2018-09-14
CNPCT/CN2018/105675 2018-09-14
CN202211142049.1A CN115636833B (zh) 2018-09-14 2019-09-16 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途
CN201980060250.5A CN112752758B (zh) 2018-09-14 2019-09-16 作为ATM激酶选择性调节剂的咪唑并[4,5-c]噌啉-2-酮化合物及其用途
PCT/CN2019/105951 WO2020052688A1 (en) 2018-09-14 2019-09-16 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980060250.5A Division CN112752758B (zh) 2018-09-14 2019-09-16 作为ATM激酶选择性调节剂的咪唑并[4,5-c]噌啉-2-酮化合物及其用途

Publications (2)

Publication Number Publication Date
CN115636833A CN115636833A (zh) 2023-01-24
CN115636833B true CN115636833B (zh) 2024-11-29

Family

ID=69777300

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211142049.1A Active CN115636833B (zh) 2018-09-14 2019-09-16 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途
CN201980060250.5A Active CN112752758B (zh) 2018-09-14 2019-09-16 作为ATM激酶选择性调节剂的咪唑并[4,5-c]噌啉-2-酮化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980060250.5A Active CN112752758B (zh) 2018-09-14 2019-09-16 作为ATM激酶选择性调节剂的咪唑并[4,5-c]噌啉-2-酮化合物及其用途

Country Status (9)

Country Link
US (1) US12226414B2 (enExample)
EP (2) EP3849984B1 (enExample)
JP (2) JP7436465B2 (enExample)
KR (1) KR102813324B1 (enExample)
CN (2) CN115636833B (enExample)
AU (1) AU2019339006B2 (enExample)
CA (1) CA3111994A1 (enExample)
ES (1) ES3001444T3 (enExample)
WO (1) WO2020052688A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115636833B (zh) * 2018-09-14 2024-11-29 苏州赞荣医药科技有限公司 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途
AU2021433713A1 (en) 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
CN115304598B (zh) * 2021-08-25 2024-05-31 石药集团中奇制药技术（石家庄）有限公司 一种杂环类化合物及其制备方法和用途
GB202114704D0 (en) * 2021-10-14 2021-12-01 Univ Birmingham ATM inhibition
MX2024009184A (es) * 2022-01-26 2024-07-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuesto que contiene grupo hidrazino.
WO2025183591A1 (ru) * 2024-02-29 2025-09-04 Федеральное государственное унитарное предприятие "Всероссийский научно-исследовательский институт автоматики им. Н.Л. Духова" (ФГУП "ВНИИА") Производные 2н-[1,4]оксазино- и 2h-[1, 4]тиазино[3,2-c]хинолин-3(4h)-онов в качестве ингибиторов атм и dna-pk киназ

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
NO2714752T3 (enExample) 2014-05-08 2018-04-21
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN108884084A (zh) 2016-03-21 2018-11-23 阿斯利康(瑞典)有限公司 噌啉-4-胺化合物及其在治疗癌症中的用途
GB201608227D0 (en) 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2019057757A1 (en) * 2017-09-20 2019-03-28 Astrazeneca Ab 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CN115636833B (zh) * 2018-09-14 2024-11-29 苏州赞荣医药科技有限公司 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kurt G. Pike，等.The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one). Journal of Medicinal Chemistry.2018,第61卷(第9期),3823−3841. *

Also Published As

Publication number Publication date
JP7436465B2 (ja) 2024-02-21
KR20210061337A (ko) 2021-05-27
EP4516318A2 (en) 2025-03-05
CN112752758B (zh) 2023-05-23
EP3849984A1 (en) 2021-07-21
EP3849984B1 (en) 2024-11-13
US12226414B2 (en) 2025-02-18
EP3849984A4 (en) 2022-06-01
EP3849984C0 (en) 2024-11-13
EP4516318A3 (en) 2025-04-30
WO2020052688A1 (en) 2020-03-19
KR102813324B1 (ko) 2025-05-26
US20220047595A1 (en) 2022-02-17
AU2019339006B2 (en) 2024-03-14
ES3001444T3 (en) 2025-03-05
JP2024054247A (ja) 2024-04-16
CN115636833A (zh) 2023-01-24
CN112752758A (zh) 2021-05-04
JP7706585B2 (ja) 2025-07-11
AU2019339006A1 (en) 2021-04-01
CA3111994A1 (en) 2020-03-19
JP2022500428A (ja) 2022-01-04

Similar Documents

Publication Publication Date Title
CN115636833B (zh) 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途
EP3768671B1 (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
CN109952295B (zh) 一种cdk4/6抑制剂及其制备方法和应用
ES2670416T3 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento de cáncer
US20240376123A1 (en) Kras g12d inhibitors and uses thereof
KR20210061329A (ko) 항종양제로서의 퀴나졸린 유도체
CN111153899A (zh) 一种取代吡啶化合物、其制备方法和用途
KR20230068412A (ko) Cbp/ep300 브로모도메인 억제제로서의 헤테로시클릭 화합물
AU2025203211A1 (en) ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS
CN111094244B (zh) 吡啶基吡啶酮化合物
CN116134022A (zh) Atr抑制剂和其用途
JP7833477B2 (ja) 血管拡張性失調症変異（ａｔｍ）キナーゼの選択的モジュレーターおよびその使用
TWI894448B (zh) Ctla-4小分子降解劑及其應用
US20250235456A1 (en) Methods of use for aza-quinazoline compounds
CN121816351A (zh) 人源酪蛋白水解蛋白酶p激动剂及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant